non-small-cell-lung-cancer

Documents about non-small-cell-lung-cancer

• Non-small cell lung cancer and tumor-educated platelets: screening of biomarkers and construction of a prognostic model.#685621NCBI PubMed Central
• Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)#806434ClinicalTrials.gov
• Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)#807918ClinicalTrials.gov
• Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.#405169ClinicalTrials.gov
• Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC#148772ClinicalTrials.gov
• Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: Implications for intervention#153472PMC Full-Text (OAI)
• Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC#346920ClinicalTrials.gov
• ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation#417534ClinicalTrials.gov
• Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in Non-Small Cell Lung Cancer (NSCLC): Pilot Study#800946ClinicalTrials.gov
• Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer#811681ClinicalTrials.gov
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma#184850ClinicalTrials.gov
• Uniportal Robotic-Assisted Versus Video-Assisted Thoracoscopic Surgery for Anatomical Lung Resection in Non-Small Cell Lung Cancer: A Comparative Single-Center Cohort Study.#275286NCBI PubMed Central
• Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.#480979NCBI PubMed Central
• Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer#146448ClinicalTrials.gov
• BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery#683077ClinicalTrials.gov
• Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung#806179ClinicalTrials.gov
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors#814039ClinicalTrials.gov
• Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC#387147ClinicalTrials.gov
• A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)#841484ClinicalTrials.gov
• A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants#805503ClinicalTrials.gov
• Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy#136304ClinicalTrials.gov
• Microwave hyperthermia enhances radiosensitivity of highly invasive non-small cell lung cancer cells via inhibiting Sonic Hedgehog signaling pathway#307764Figshare
• Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy#67866ClinicalTrials.gov
• Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases#841311ClinicalTrials.gov
• Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study#157665HAL (France)
• Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC#394755ClinicalTrials.gov
• From cytology to systems pathology: Decoding the molecular heterogeneity of resectable non-small-cell lung cancer#411898IRIS
• Synergistic effects and clinical utilization of radioimmunotherapy for brain metastases from driver mutation-negative non-small cell lung cancer.#465111NCBI PubMed Central
• Higher Blood-to-Tissue Tumor Mutational Burden Ratio Is Associated With Poorer Overall Survival in Advanced Non-Small Cell Lung Cancer#651104bioRxiv / medRxiv
• From phenotypic associations to clinical triage: promise and pitfalls of fusion-prediction models in non-small cell lung cancer.#685602NCBI PubMed Central
• A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib#805551ClinicalTrials.gov
• Comparison of Diagnostic and Therapeutic Efficacy of EBUS-TBNA/EUS-FNA and TEMLA in Operable NSCLC.#807860ClinicalTrials.gov
• A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer#813029ClinicalTrials.gov
• WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC#825131ClinicalTrials.gov
• Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies#832128ClinicalTrials.gov
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine#454035ClinicalTrials.gov
• A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases#833944ClinicalTrials.gov
• Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease#321701ClinicalTrials.gov
• HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors#812705ClinicalTrials.gov
• Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors#830429ClinicalTrials.gov
• Socioeconomic Determinants of Guideline-Concordant Therapy for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis from Appalachian and Non-Appalachian Ohio, 2004-2015#390893bioRxiv / medRxiv
• Chidamide impedes the progression of non-small cell lung cancer by inhibiting the METTL3/EPHA7 pathway#314659Figshare
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors#833985ClinicalTrials.gov
• Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers#842057ClinicalTrials.gov
• A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus#807161ClinicalTrials.gov
• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study#11468HAL (France)
• Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program#152394ClinicalTrials.gov
• Proposal of real-world solutions for the implementation of predictive biomarker testing in patients with operable non-small cell lung cancer#153533HAL (France)
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors#180214ClinicalTrials.gov
• SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC#245495ClinicalTrials.gov